IL126772A0 - Monoclonal antibody of cea conjugates comprising said antibody and their therapeutic use in an adept system - Google Patents
Monoclonal antibody of cea conjugates comprising said antibody and their therapeutic use in an adept systemInfo
- Publication number
- IL126772A0 IL126772A0 IL12677297A IL12677297A IL126772A0 IL 126772 A0 IL126772 A0 IL 126772A0 IL 12677297 A IL12677297 A IL 12677297A IL 12677297 A IL12677297 A IL 12677297A IL 126772 A0 IL126772 A0 IL 126772A0
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- monoclonal antibody
- therapeutic use
- cdr3
- chain cdr1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9609405.7A GB9609405D0 (en) | 1996-05-04 | 1996-05-04 | Protein |
GBGB9703103.3A GB9703103D0 (en) | 1997-02-14 | 1997-02-14 | Protein |
PCT/GB1997/001165 WO1997042329A1 (en) | 1996-05-04 | 1997-04-29 | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
Publications (1)
Publication Number | Publication Date |
---|---|
IL126772A0 true IL126772A0 (en) | 1999-08-17 |
Family
ID=26309272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12677297A IL126772A0 (en) | 1996-05-04 | 1997-04-29 | Monoclonal antibody of cea conjugates comprising said antibody and their therapeutic use in an adept system |
Country Status (19)
Country | Link |
---|---|
US (2) | US6277599B1 (xx) |
EP (1) | EP0896626B1 (xx) |
JP (1) | JP2000510692A (xx) |
CN (1) | CN1217750A (xx) |
AT (1) | ATE350478T1 (xx) |
AU (1) | AU719513B2 (xx) |
BR (1) | BR9708910A (xx) |
CA (1) | CA2250579A1 (xx) |
CZ (1) | CZ353698A3 (xx) |
DE (1) | DE69737188T2 (xx) |
ES (1) | ES2279539T3 (xx) |
HU (1) | HUP9901562A3 (xx) |
IL (1) | IL126772A0 (xx) |
NO (1) | NO985120L (xx) |
NZ (1) | NZ331978A (xx) |
PL (1) | PL329871A1 (xx) |
SK (1) | SK150298A3 (xx) |
TR (1) | TR199802227T2 (xx) |
WO (1) | WO1997042329A1 (xx) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997042329A1 (en) * | 1996-05-04 | 1997-11-13 | Zeneca Limited | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
WO1998035988A1 (en) * | 1997-02-14 | 1998-08-20 | Zeneca Limited | Proteins |
GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
AU752494B2 (en) * | 1998-02-25 | 2002-09-19 | Dow Chemical Company, The | High affinity humanized ANTI-CEA monoclonal antibodies |
JP2002530080A (ja) * | 1998-11-19 | 2002-09-17 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 免疫グロブリン・スーパーファミリー・タンパク質 |
CA2391925A1 (en) * | 1999-11-18 | 2001-05-25 | Oxford Biomedica (Uk) Limited | Antibodies |
GB2371803A (en) * | 1999-11-18 | 2002-08-07 | Oxford Biomedica Ltd | Antibodies |
DE50112965D1 (de) * | 2000-04-22 | 2007-10-18 | Pharmedartis Gmbh | Apoptotika |
GB0210783D0 (en) * | 2002-05-10 | 2002-06-19 | Polonelli Luciano | Anti-microbial polypeptides |
KR100604037B1 (ko) * | 2002-08-02 | 2006-07-24 | 주식회사유한양행 | 항체 경쇄 카파 발현벡터 |
US20050008618A1 (en) * | 2003-02-27 | 2005-01-13 | Howard Kaufman | Composition for delivering an agent to a target cell and uses thereof |
EP1606387A4 (en) * | 2003-03-04 | 2008-04-23 | Alexion Pharma Inc | VECTORS USED TO PRODUCE CONSTANT HYBRID AREAS |
ATE517920T1 (de) * | 2003-04-23 | 2011-08-15 | Medarex Inc | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) |
WO2005058236A2 (en) * | 2003-12-12 | 2005-06-30 | Genencor International, Inc. | Cab molecules |
US20050232919A1 (en) | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
JP4699450B2 (ja) * | 2004-04-15 | 2011-06-08 | ジェネンコー・インターナショナル・インク | Cab分子、ceaを対象とするadept構築 |
EP2366717A3 (en) | 2004-10-29 | 2011-12-14 | University of Southern California | Combination Cancer Immunotherapy with Co-Stimulatory Molecules |
ES2429340T3 (es) | 2005-03-10 | 2013-11-14 | Morphotek, Inc. | Anticuerpos anti-mesotelina |
AU2006241099B2 (en) | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
JP2009510046A (ja) | 2005-09-30 | 2009-03-12 | メドイミューン・リミテッド | インターロイキン−13抗体組成物 |
EP2046375B1 (en) | 2006-07-20 | 2017-04-05 | The General Hospital Corporation | Methods and compositions for the selective activation of protoxins through combinatorial targeting |
US8043830B2 (en) * | 2008-02-01 | 2011-10-25 | The Regents Of The University Of California | Biotin-ligase system for secretion of biotinylated protein |
CN101607985B (zh) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体,包含其的组合物,及其用途 |
CN101704892B (zh) * | 2009-12-09 | 2014-02-12 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗uPAR人源化抗体及其编码基因与应用 |
NZ601271A (en) | 2010-01-28 | 2014-09-26 | Glaxo Group Ltd | Cd127 binding proteins |
CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
CN102526707B (zh) * | 2012-01-13 | 2015-04-22 | 成都博发生物技术有限公司 | 共刺激因子及融合蛋白的新用途 |
RU2493166C1 (ru) * | 2012-04-09 | 2013-09-20 | Общество с ограниченной ответственностью "Технофарма" | Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка |
CN102838676A (zh) * | 2012-09-26 | 2012-12-26 | 李彬 | 一种癌胚抗原单抗及包含该抗体的芯片以及应用 |
SI2839860T1 (sl) | 2012-10-12 | 2019-07-31 | MedImmune Limited, | Pirolobenzodiazepini in njihovi konjugati |
AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CN110526971B (zh) | 2013-04-29 | 2023-06-30 | 泰华制药澳大利亚公司 | 抗-CD38抗体和与致弱干扰素α-2B的融合体 |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10544199B2 (en) | 2014-10-29 | 2020-01-28 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha 2B variants |
JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド (エイチケイ) リミテッド | 多重特異性Fab融合タンパクおよびその使用 |
CA3030926A1 (en) | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd47 combination therapy |
CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
CN106749667B (zh) * | 2016-12-04 | 2020-07-14 | 深圳市国创纳米抗体技术有限公司 | 一种抗癌胚抗原的纳米抗体及其应用 |
KR20210016562A (ko) | 2018-05-23 | 2021-02-16 | 에이디씨 테라퓨틱스 에스에이 | 분자 애쥬번트 |
EP4021464A4 (en) * | 2019-08-27 | 2024-01-03 | Univ Pennsylvania | SYNTHETIC CARS FOR TREATING IL13Ra2 POSITIVE HUMAN OR CANINE TUMORS |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8809616D0 (en) | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
WO1997042329A1 (en) * | 1996-05-04 | 1997-11-13 | Zeneca Limited | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
-
1997
- 1997-04-29 WO PCT/GB1997/001165 patent/WO1997042329A1/en active IP Right Grant
- 1997-04-29 JP JP09539625A patent/JP2000510692A/ja active Pending
- 1997-04-29 CN CN97194390A patent/CN1217750A/zh active Pending
- 1997-04-29 EP EP97918258A patent/EP0896626B1/en not_active Expired - Lifetime
- 1997-04-29 US US09/171,945 patent/US6277599B1/en not_active Expired - Fee Related
- 1997-04-29 HU HU9901562A patent/HUP9901562A3/hu unknown
- 1997-04-29 ES ES97918258T patent/ES2279539T3/es not_active Expired - Lifetime
- 1997-04-29 DE DE69737188T patent/DE69737188T2/de not_active Expired - Fee Related
- 1997-04-29 PL PL97329871A patent/PL329871A1/xx unknown
- 1997-04-29 IL IL12677297A patent/IL126772A0/xx unknown
- 1997-04-29 AU AU26455/97A patent/AU719513B2/en not_active Ceased
- 1997-04-29 CA CA002250579A patent/CA2250579A1/en not_active Abandoned
- 1997-04-29 AT AT97918258T patent/ATE350478T1/de not_active IP Right Cessation
- 1997-04-29 TR TR1998/02227T patent/TR199802227T2/xx unknown
- 1997-04-29 NZ NZ331978A patent/NZ331978A/xx unknown
- 1997-04-29 SK SK1502-98A patent/SK150298A3/sk unknown
- 1997-04-29 CZ CZ983536A patent/CZ353698A3/cs unknown
- 1997-04-29 BR BR9708910A patent/BR9708910A/pt not_active Application Discontinuation
-
1998
- 1998-11-03 NO NO985120A patent/NO985120L/no not_active Application Discontinuation
-
2001
- 2001-07-23 US US09/910,059 patent/US6903203B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HUP9901562A3 (en) | 2000-06-28 |
JP2000510692A (ja) | 2000-08-22 |
PL329871A1 (en) | 1999-04-12 |
AU2645597A (en) | 1997-11-26 |
DE69737188T2 (de) | 2007-10-11 |
US20020142359A1 (en) | 2002-10-03 |
CA2250579A1 (en) | 1997-11-13 |
CN1217750A (zh) | 1999-05-26 |
US6277599B1 (en) | 2001-08-21 |
ATE350478T1 (de) | 2007-01-15 |
WO1997042329A1 (en) | 1997-11-13 |
ES2279539T3 (es) | 2007-08-16 |
TR199802227T2 (xx) | 2000-07-21 |
DE69737188D1 (de) | 2007-02-15 |
BR9708910A (pt) | 1999-08-03 |
US6903203B2 (en) | 2005-06-07 |
NO985120D0 (no) | 1998-11-03 |
HUP9901562A2 (hu) | 1999-08-30 |
AU719513B2 (en) | 2000-05-11 |
NZ331978A (en) | 2000-05-26 |
EP0896626B1 (en) | 2007-01-03 |
SK150298A3 (en) | 1999-04-13 |
CZ353698A3 (cs) | 1999-02-17 |
NO985120L (no) | 1998-12-29 |
EP0896626A1 (en) | 1999-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL126772A0 (en) | Monoclonal antibody of cea conjugates comprising said antibody and their therapeutic use in an adept system | |
CA2250080A1 (en) | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications | |
CA2093928A1 (en) | Monoclonal antibodies for detection and treatment of cancer | |
YU45501A (sh) | Humana monoklonalna antitela za ctla-4 | |
AU2555297A (en) | Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen | |
DE69119211D1 (de) | Cdr-gepfropfte anti-cea-antikörper und ihre herstellung | |
WO2004032857A8 (en) | Antibody therapy | |
AU5414996A (en) | Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma | |
EP1415998A3 (en) | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies | |
WO1996020219A3 (en) | Murine monoclonal anti-idiotype antibody 3h1 | |
USRE38008E1 (en) | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof | |
AU628948B2 (en) | Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof | |
IE880976L (en) | Human tumour-associated antigen | |
AU584690B2 (en) | E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma | |
ES2000615A6 (es) | Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3" | |
CA2380066A1 (en) | Antitumor antibodies, proteins, and uses thereof | |
AU5728699A (en) | Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases | |
ZA941645B (en) | Antibodies specifically reactive against human prostate specific antigen. | |
ATE84069T1 (de) | Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist. | |
KR930013103A (ko) | 종양 관련의 모노클로날 항체 88bv59 | |
张学庸 et al. | Use of MG series monoclonal antibodies in the diagnosis and experimental targeting therapy of gastric cancer | |
AU6162794A (en) | Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor | |
SE9503044D0 (sv) | Antibodies for use in cancer therapy and diagnosis |